Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 17, Status: Withdrawn

Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Date of authorisation: 25/04/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Date of authorisation: 15/09/2022, Revision: 20, Status: Authorised

Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) annual activity report 2025

Minutes of the Management Board meeting: 17-18 December 2025

Human medicines European public assessment report (EPAR): Yeytuo, lenacapavir, Date of authorisation: 25/08/2025, Revision: 1, Status: Authorised

European Medicines Agency (EMA) stakeholder relations management framework

Human medicines European public assessment report (EPAR): Adenuric, febuxostat, Date of authorisation: 21/04/2008, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Remsima, infliximab, Date of authorisation: 10/09/2013, Revision: 45, Status: Authorised